Areteos Group gives its clients direct access to senior healthcare operators — for market intelligence, deal work, and portfolio improvement. No overhead, rapid actionable insights, and focused expert execution.
The Name
A place to exercise excellence
From ἀρετή (aretē) + -eos.
Areteos — from the Greek ἀρετή, excellence as a practiced discipline, and -eos, the suffix that makes it a place where that discipline is actively exercised.
In classical philosophy, aretē was never a fixed quality. It was a dynamic, practiced state — the result of deliberate effort, sound judgement, and continual refinement, always in the service of others.
Areteos Group brings the quality of thinking, rigor of analysis, and integrity of counsel to every engagement, without exception.
Why Areteos
What sets us apart
01Real-world experience
We are first and foremost healthcare operators who ran global billion-dollar P&Ls, optimized go-to-market strategies, scaled operations, improved quality systems and performance, and navigated complex regulatory regimes across the US, Europe, and Asia. The market analysis, diligence, and operating advice you receive comes from someone who has made these decisions with real capital at stake. Experience that matters when speed and conviction are what a deal requires.
02Senior expertise, on demand
You engage directly with seasoned practitioners — on a specific mandate, at the pace you dictate. For broader coverage, we assemble the right specialists from our network transparently and without markup. The right expertise, calibrated to the work at hand.
03Exclusive focus on the healthcare sector
We work exclusively in middle market healthcare — spanning services, consumables, and devices — across global markets. This means faster market orientation, sharper diligence, and better networks than any generalist firm can offer. We know the regulatory landscape, the key players, and the commercial dynamics because we have operated within them, not merely studied them. Deep vertical knowledge to accelerate speed to decision.
04Innovation at the core
Healthcare value creation increasingly depends on the ability to identify, evaluate, and accelerate innovation — whether in care delivery models, AI integration and digital workflows, or product development. Hands-on experience in front-end design, product lifecycle management, and innovation-driven go-to-market strategy — applied across the diligence process and portfolio value creation.
A seasoned health tech and med device executive with over fifteen years of experience driving strategy, innovation, and performance across global markets.
Yuri Haverman founded Areteos Group to bring genuine operating depth directly to the private equity firms, strategics, and portfolio companies that need it most. His career spans the full spectrum of healthcare — from clinical science through commercial execution — across the United States, Europe, and Asia.
Most recently, Yuri served as Vice President and General Manager at Becton Dickinson (BD), one of the world's leading medical technology companies, where he led a large global business spanning infusion preparation and delivery — encompassing instruments, software, and consumables. He held full commercial and operational accountability across North and South America, EMEA, and China. During his tenure, he delivered consistent profitable growth, led successful multi-market product launches, and drove significant improvement in business profitability through a combination of commercial discipline and operational redesign.
Before that general management role, Yuri built deep expertise in strategy, business development, and innovation through his work in BD's Strategic Innovation group, as well as in start-ups and PE/VC environments. He has experience in strategy articulation and deployment at the enterprise and business unit level, product and portfolio lifecycle management, post-merger integration, and the design and launch of new business models. A trained BioDesign Fellow, he brings structured innovation methodology and deep customer insights to the evaluation of novel care delivery approaches, digital health applications, and medical technology development.
Yuri holds an MBA in Strategy and Finance from the University of Michigan's Ross School of Business, a BioDesign Fellowship from the University of Michigan, and a Bachelor of Science in Medicine from the Hebrew University of Jerusalem. He is fluent in English, Hebrew, and Russian, and conversational in French. He splits his time between the United States and Switzerland, with active networks across the European, British, and North American healthcare markets.
Philosophy
"The standard I hold on every mandate is the same I held when running large, complex businesses: commitment to customer success, full transparency, informed risk management, bias for action, and accountability for outcomes."
Every engagement at Areteos Group receives the same level of rigor, whether it is a focused diligence question or a multi-year strategic partnership. And when Areteos steps into a fractional leadership role, it operates as a full member of the management team — with real accountability for results, not as a periodic advisor collecting a retainer.
Education
MBA Strategy & Finance — University of Michigan
Fellowship
BioDesign Fellow — University of Michigan
Medicine
BSc Medicine — Hebrew University of Jerusalem
Location
US & Switzerland · Global coverage
Languages
English · Hebrew · Russian · French
Services
Full cycle. Right expertise.
From investment thesis validation through to portfolio company exit — and a network of sector specialists assembled around mandates that require broader coverage. The right expertise, scoped to the work.
Healthcare ServicesMedical ConsumablesMedical Devices & MedTechInnovation & BioDesignMiddle Market PEUS · EU · UK
Investment Lifecycle
From origination to exit
01Investment Thesis Validation
Market sizing, competitive landscaping, and regulatory mapping to stress-test your thesis before capital is committed. We evaluate market attractiveness, structural dynamics, and innovation trajectories across healthcare services, consumables, and devices in the EU, UK, and US markets.
02Deal Origination
Proprietary sourcing through a cross-border healthcare network built over two decades of operating in these markets. We identify and qualify off-market opportunities aligned to your mandate before they reach the broader process — with a particular focus on innovation-driven companies and emerging care models.
03Due Diligence
Commercial, operational, regulatory, and innovation diligence grounded in real operating experience. We evaluate management quality, product and technology pipelines, market access strategy, and competitive positioning with the depth that comes from having run businesses in these sectors — without slowing your deal timeline.
04Transaction Support
Hands-on support through close — management assessment, integration planning, value creation roadmap development, and 100-day agenda design alongside your deal team. We translate diligence findings into actionable operating priorities from day one.
05Portfolio Company Value Enhancement
Embedded operating partnership post-close — driving revenue performance, operational improvement, product and commercial innovation, and exit preparation. Ranges from structured advisory to full operational involvement, depending on what the business requires.
Fractional C-Suite
Senior leadership, on your terms
When a portfolio company needs experienced leadership — for a transformation, a growth phase, or a leadership gap — we step in as a senior operator with full accountability. Not an interim placement agency. A working executive with skin in the outcome.
Chief Executive OfficerFractional · Interim
CEO-level leadership through transitions, turnarounds, or periods of accelerated growth — with full board-level accountability and direct operational ownership. Particularly suited to businesses navigating a strategic inflection point or preparing for a sale process.
Chief Operating OfficerFractional · Interim
Operational grip across commercial execution, supply chain, and multi-site management — for businesses scaling post-acquisition, integrating a bolt-on, or improving operational performance ahead of exit.
Chief Commercial OfficerFractional · Interim
Value proposition, go-to-market strategy and business models, sales force structure, pricing, and channel management — for healthcare businesses entering new geographies, launching new products, or rebuilding commercial performance after a period of underinvestment.
Chief Product OfficerFractional · Advisory
Structured innovation leadership for portfolio companies with product development, digital health, or technology transformation programs — applying rigorous frameworks and commercial stage-gate discipline to accelerate time-to-market and de-risk investment.
On-Demand Network
The right specialists, assembled per mandate
When a mandate requires broader coverage, we assemble a targeted team from our network of senior healthcare professionals. Every specialist is engaged transparently, without markup, and scoped precisely to the work required.
Clinical & Medical Affairs
Physicians and clinical specialists with deep sub-sector knowledge across acute care, ambulatory, diagnostics, and surgical markets — for clinical validation, KOL mapping, and evidence strategy in diligence and portfolio work.
Regulatory, Quality & Market Access
EU MDR, FDA 510(k)/PMA, and UKCA expertise for device and consumable diligence. Quality systems audits and remediation to ensure compliance. Reimbursement, HEOR, and pricing specialists — critical for evaluating the true commercial pathway of innovation-stage assets.
Commercial & Go-to-Market
Senior commercial operators with direct experience building and running sales organizations in healthcare services, medical devices, and consumables — for commercial diligence, distribution strategy, and portfolio sales transformation.
Digital Health & Technology
Specialists in digital health platforms, software as a medical device (SaMD), health data infrastructure, and AI-enabled decision support — for evaluating innovation assets and supporting portfolio technology strategy.
Contact
Let's talk about your needs.
A specific mandate, a strategic question, or an initial conversation to explore fit. We respond within 24 hours and keep it straightforward.
Switzerland · US · EU · UK
We respond within 24 hours. Conversations are confidential.
English · Hebrew · Russian · French
Message Received
Thank you for reaching out.
We have received your message and will respond within 24 hours. We look forward to learning about your mandate and exploring how Areteos Group can be of service.
